NASDAQ:BIOC - Biocept, Inc.
$1.06
 $0.03
+2.92%
4:00PM EDT
2019-07-22
Biocept, Inc. is an early commercial-stage molecular oncology diagnostics company. The Company develops and commercializes circulating tumor cell (CTC) and circulating tumor deoxyribonucleic acid (ctDNA), assays utilizing a standard blood sample, or liquid biopsy. The Company's Target-Selector offering is based on an internally developed, microfluidics-based CTC capture and analysis platform, with enabling features that change how CTC testing can be used by clinicians by providing biomarker detection and monitoring requiring only a standard blood sample. The ctDNA technology enables mutation detection and is applicable to nucleic acid from CTCs or other sample types, such as blood plasma. The Company commercializes its Target-Selector assays for a range of solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), gastric cancer, colorectal cancer, prostate cancer and melanoma. Read more at  reuters.com
sector:  health care
industry:  biotechnology
the data below are updated and published after 9pm EDT each trading day
  BIOC     avg for
industry  
  avg for
sector  
42 stocks weight:  1. 78   217. 37   399. 45  
42 stocks rank:  4. 43 K 1. 27 K 716. 99  
# analyst opinions:  3. 00   13. 21   13. 71  
mean recommendation:  2. 00   2. 10   2. 04  

quick ratio:  2. 59   5. 49   1. 88  
current ratio:  2. 72   5. 87   2. 36  

target price low:  0. 70   83. 44   114. 90  
target price avg:  1. 41   106. 20   137. 90  
target price high:  3. 00   132. 30   158. 97  
1-yr high:  6. 25   111. 86   142. 57  
last close:  1. 03   86. 79   125. 44  
50-day avg:  1. 08   86. 68   122. 63  
200-day avg:  1. 33   89. 22   121. 38  
1-yr low:  0. 69   69. 78   100. 51  
volume:  318. 87 K 2. 62 M 3. 43 M
50-day avg volume:  4. 52 M 3. 20 M 4. 16 M
200-day avg volume:  2. 44 M 2. 99 M 4. 75 M

1-day return:  -0. 01 % -1. 30 % -0. 99 %
this week return:  -0. 01 % 0. 45 % -0. 20 %
12-wk return:  8. 41 % 0. 94 % 4. 84 %
52-wk return:  -83. 95 % -1. 30 % 10. 55 %

enterprise value (EV):  8. 34 M 45. 10 B 122. 38 B
market cap:  19. 43 M 38. 96 B 108. 40 B
EBITDA:  -23. 00 M 4. 20 B 8. 19 B
enterprise multiple (EV/EBITDA):  -0. 36   5. 38   11. 93  
enterprise/revenue (EV/R):  2. 40   57. 92   10. 21  
total revenue:  3. 47 M 9. 91 B 39. 98 B
total debt:  3. 48 M 10. 90 B 17. 48 B
debt/equity:  24. 82   57. 18   120. 05  
net income (common):  -24. 87 M 2. 07 B 4. 05 B

shares outstanding:  0. 00   538. 09 M 1. 24 B
shares:  17. 66 M 548. 00 M 1. 22 B
shares short:  764. 54 K 10. 98 M 11. 87 M
shares short prior month:  2. 23 M 9. 32 M 12. 05 M
short ratio:  0. 29   5. 60   3. 34  
short % of float:  4. 06 % 6. 48 % 2. 64 %
total cash/share:  0. 78   10. 98   9. 19  
total cash:  14. 76 M 5. 93 B 6. 10 B
free cash flow:  -13. 36 M 2. 92 B 4. 55 B
operating cash flow:  -22. 03 M 3. 80 B 5. 78 B

book value:  0. 74   13. 35   27. 45  
price/book:  1. 39   4. 60   8. 78  
gross profits:  -6. 80 M 7. 44 B 36. 13 B
operating margins:  -687. 50 % -308. 40 % -28. 55 %
EBITDA margins:  0. 00 % 13. 17 % 23. 38 %
profit margins:  0. 00 % 10. 44 % 14. 18 %
gross margins:  -194. 62 % 35. 80 % 55. 40 %

1-yr max volatility:  139. 46 % --- ---
1-yr mean volatility:  6. 01 % 1. 66 % 1. 03 %

1-yr EPS:  -5. 21   2. 10   4. 23  
forward EPS:  -0. 49   3. 45   7. 10  
P/E:  -0. 20   1. 90   32. 10  
forward P/E:  -2. 10   6. 46   15. 47  
PE/G:  -0. 01   0. 70   -0. 54  
growth:  26. 90 % 265. 63 % 79. 11 %
earnings high:  -0. 00   0. 89   1. 68  
earnings avg:  -0. 00   0. 70   1. 57  
earnings low:  -0. 00   0. 46   1. 46  
revenue high:  1. 02 M 2. 57 B 11. 07 B
revenue avg:  1. 02 M 2. 51 B 10. 91 B
revenue low:  1. 02 M 2. 45 B 10. 73 B
return on assets:  -81. 33 % -2. 34 % 5. 28 %
return on equity:  -214. 30 % -90. 08 % 133. 53 %
revenue growth:  26. 90 % 265. 25 % 73. 68 %
revenue/share:  0. 73   12. 72   60. 04  

beta (1yr vs S&P500):  -0. 45   1. 27   0. 91  
sharpe (1yr):  0. 00   0. 16   0. 77  

held % insiders:  0. 23 % 6. 06 % 3. 29 %
held % institutions:  13. 41 % 78. 22 % 69. 37 %

Research more with google or yahoo!
the data below are updated and re-published at 8pm EDT after each trading day

2019-07-21 : BIOC
.    101.009 =       101.009 :: --> INITIAL WEIGHT <--
.    - 5.215 =        95.794 :: earnings per-share addition
.                               --> FUNDAMENTALS <--
.    x 1.943 =       186.089 :: P/E factor
.    x 2.209 =       411.063 :: PE/G factor
.    x 1.614 =       663.616 :: beta factor
.    x 0.638 =       423.155 :: sharpe factor
.    x 2.464 =      1042.601 :: current ratio factor
.    x 1.276 =      1330.668 :: quick ratio factor
.    x 1.934 =      2573.568 :: short ratio factor
.    x 1.443 =      3714.178 :: revenue growth factor
.    x 1.042 =      3868.326 :: EV/R factor
.    x 1.007 =      3895.044 :: price-to-book factor
.    x 0.999 =      3890.875 :: debt-to-revenue factor
.    x 1.197 =      4659.311 :: debt-to-equity factor
.                               --> PERFORMANCE <--
.    x 2.121 =      9881.435 :: sector+industry 1-year gains factor
.    x 1.009 =      9974.598 :: industry 12-weeks return factor
.    x 1.308 =     13045.663 :: industry 2-weeks return factor
.    / 2.236 =      5835.544 :: overall "drift" factor
.    x 0.011 =         66.29 :: largest single-day jump factor
.    x 0.062 =         4.105 :: low price factor
.    x 0.009 =         0.035 :: notable returns + performance factor
.                               --> PROJECTIONS <--
.     x 0.24 =         0.009 :: forward EPS factor
.    x 0.724 =         0.006 :: forward P/E factor
.    x 1.185 =         0.007 :: industry recommendation factor
.    x 2.122 =         0.015 :: company recommendation factor
.    x 1.003 =         0.016 :: factor historical industry gain for week 29
.    x 0.914 =         0.014 :: target low factor
.    x 1.202 =         0.017 :: target mean factor
.    x 1.058 =         0.018 :: target high factor
.   x 10.495 =         0.189 :: spline projection factor
.                               --> FINAL ADJUSTMENTS <--
.    + 1.596 =         1.785 :: add/subtract for investor sentiment
.                               --> FINAL WEIGHT <--
.                      1.785 :: FINAL WEIGHT for NASDAQ:BIOC


 


News feed RSS items generated from finance.google.com

News feed formatting by feed2js.org